BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38642125)

  • 21. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Robotic pelvic exenteration and extended pelvic resections for locally advanced or synchronous rectal and urological malignancy.
    Williams M; Perera M; Nouhaud FX; Coughlin G
    Investig Clin Urol; 2021 Jan; 62(1):111-120. PubMed ID: 33381928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival.
    Labori KJ; Guren MG; Brudvik KW; Røsok BI; Waage A; Nesbakken A; Larsen S; Dueland S; Edwin B; Bjørnbeth BA
    Colorectal Dis; 2017 Aug; 19(8):731-738. PubMed ID: 28181384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 26. Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.
    Grosso F; Mandalà M; Maglione V; Berretta L; Mariani N; Rossi M; Piovano PL; Drago D; Summa M; Franzone P; Musante F; Spinoglio G
    Tumori; 2012 Nov; 98(6):689-95. PubMed ID: 23389353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.
    Sanfilippo NJ; Crane CH; Skibber J; Feig B; Abbruzzese JL; Curley S; Vauthey JN; Ellis LM; Hoff P; Wolff RA; Brown TD; Cleary K; Wong A; Phan T; Janjan NA
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):176-83. PubMed ID: 11516868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Exploration on neoadjuvant chemoradiation in the treatment for locally advanced low rectal cancer].
    Yu BM; Zhang M; Peng LH; Bian GW; Wu WQ; Chen LW; Fu J; Fei CS
    Zhonghua Wai Ke Za Zhi; 2009 Oct; 47(20):1540-3. PubMed ID: 20092741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?
    Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD
    Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?
    Rahbari NN; Ulrich AB; Bruckner T; Münter M; Nickles A; Contin P; Löffler T; Reissfelder C; Koch M; Büchler MW; Weitz J
    Ann Surg; 2011 Mar; 253(3):522-33. PubMed ID: 21209587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of high-dose rate (HDR) brachytherapy for patients with prostate cancer and history of prior chemoradiation for rectal cancer: A case series.
    Thomas H; Chen JJ; Abdul-Baki H; Sabbagh A; Shaheen H; Chau OW; Malik N; Ayoub A; Hassanzadeh C; Hsu IC; Mohamad O
    Brachytherapy; 2024; 23(2):173-178. PubMed ID: 38160102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of locally advanced synchronous colorectal and prostate cancers: A case report.
    Tey YQ; Ravi K; Chong CS; Chiong E; Ho J; Tey JCS; Ho F
    Medicine (Baltimore); 2020 May; 99(22):e20336. PubMed ID: 32481410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
    Garlipp B; Ptok H; Schmidt U; Meyer F; Gastinger I; Lippert H
    Langenbecks Arch Surg; 2010 Nov; 395(8):1031-8. PubMed ID: 20711786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
    J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement.
    Mariathasan AB; Boye K; Giercksky KE; Brennhovd B; Gullestad HP; Emblemsvåg HL; Grøholt KK; Dueland S; Flatmark K; Larsen SG
    Eur J Surg Oncol; 2018 Aug; 44(8):1226-1232. PubMed ID: 29691115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
    Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
    Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.